Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02800148 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
A Phase 3 study of Rosacea, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 667
- Enrollment target
- 1
- Study location
NCT02800148: Completed Phase 3 study of Rosacea, sponsored by Padagis.
NCT02800148 is a Phase 3 study of Rosacea that has completed, run by Padagis. The registered enrollment target is 667 participants, above the 214-participant average among 23 other Rosacea trials with a reported enrollment target (212% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02800148, a Phase 3 study of Rosacea, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 667 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
Conditions Studied
Interventions
- DRUG Azelaic acid foam
- DRUG Azelaic acid foam - Placebo
Study Locations (1)
North Carolina
- Dermatology Consultants - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
What the finished NCT02800148 record still lists
NCT02800148 is an interventional study that assigns participants to a tested intervention. The registered 667 participants enrollment target is mid-sized for trials with a published cap, above the 214-participant average among 23 other Rosacea trials with a reported enrollment target (212% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Azelaic acid foam is the first listed.
NCT02800148 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02800148 about?
NCT02800148 is a clinical study titled "Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face". To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
What is the current status of trial NCT02800148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 2016-11. Estimated completion is 2017-10.
What conditions does trial NCT02800148 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02800148?
The interventions under investigation include: Azelaic acid foam (DRUG), Azelaic acid foam - Placebo (DRUG).
Who is sponsoring clinical trial NCT02800148?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02800148 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02800148's enrollment target sits among peer trials
667 2nd of 23 the highest of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
- NCT05006482 · 668 participants · Phase 3
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia